Prilenia is a late clinical-stage biotechnology company founded in 2018 focused on the urgent mission to develop novel therapeutics to address the progression of neurodegenerative diseases and neurodevelopmental disorders. The initial focus of the company has been on Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).
Prilenia's lead compound is pridopidine (45 mg twice daily), a first-in-class, oral, highly selective and potent investigational S1R agonist that is in pre-registration for HD and Phase 3-stage development for ALS. Prilenia holds Orphan Drug designation for pridopidine in HD and ALS in the U.S. and EU. In addition, pridopidine has received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of HD.
Prilenia is backed by a group of well-respected investors including: Forbion, Morningside, Sands Capital, SV Health Investors, Sectoral Asset Management, Talisman, Amplitude Ventures and the ALS Investment Fund.